- Home
- NTAP vs RPRX Comparison
NTAP vs RPRX Comparison
Compare NTAP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTAP
- RPRX
- Stock Information
- Founded
- NTAP 1992
- RPRX 1996
- Country
- NTAP United States
- RPRX United States
- Employees
- NTAP N/A
- RPRX N/A
- Industry
- NTAP Electronic Components
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- NTAP Technology
- RPRX Health Care
- Exchange
- NTAP Nasdaq
- RPRX Nasdaq
- Market Cap
- NTAP 16.9B
- RPRX 14.2B
- IPO Year
- NTAP 1995
- RPRX 2020
- Fundamental
- Price
- NTAP $94.44
- RPRX $33.10
- Analyst Decision
- NTAP Buy
- RPRX Strong Buy
- Analyst Count
- NTAP 17
- RPRX 4
- Target Price
- NTAP $126.00
- RPRX $42.50
- AVG Volume (30 Days)
- NTAP 1.9M
- RPRX 3.9M
- Earning Date
- NTAP 05-29-2025
- RPRX 05-08-2025
- Dividend Yield
- NTAP 2.20%
- RPRX 2.66%
- EPS Growth
- NTAP 23.16
- RPRX 37.42
- EPS
- NTAP 5.40
- RPRX 2.45
- Revenue
- NTAP $6,508,000,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- NTAP $6.78
- RPRX $31.30
- Revenue Next Year
- NTAP $4.54
- RPRX $5.82
- P/E Ratio
- NTAP $17.49
- RPRX $13.52
- Revenue Growth
- NTAP 5.29
- RPRX 1.12
- 52 Week Low
- NTAP $71.84
- RPRX $24.05
- 52 Week High
- NTAP $135.45
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- NTAP 62.54
- RPRX 57.01
- Support Level
- NTAP $91.15
- RPRX $31.97
- Resistance Level
- NTAP $93.66
- RPRX $33.00
- Average True Range (ATR)
- NTAP 2.09
- RPRX 0.71
- MACD
- NTAP 1.45
- RPRX 0.08
- Stochastic Oscillator
- NTAP 93.81
- RPRX 60.08
About NTAP NetApp Inc.
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.